The Pancreatic Cancer Drugs by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Pancreatic Cancer Drugs Market:
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
According to The Business Research Company’s Pancreatic Cancer Drugs, The pancreatic cancer drugs market size has grown steadily in recent years. It will grow from $3.83 billion in 2023 to $3.98 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to strong economic growth in emerging markets, an increasing aging population and an increasing prevalence of pancreatic cancer.
The pancreatic cancer drugs market size is expected to see steady growth in the next few years. It will grow to $4.65 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to increase in cancer incidence rates, a rise in healthcare expenditure and increasing government support. Major trends in the forecast period include focus on developing new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment, focus on increasing investments, focus on strategic collaborations and focus on product innovations.
The increasing prevalence of pancreatic cancer is expected to drive the growth of the pancreatic cancer drugs market. With the rise in several pancreatic cancer cases, the demand for drugs is expected to increase as well, which will drive the growth of the pancreatic cancer drugs market. The number of cancer cases has increased mainly due to the aging population and an increase in several people suffering from obesity. For instance, according to the American Cancer Society, in 2023 estimated about 64,050 people (33,130 men and 30,920 women) will be diagnosed with pancreatic cancer and about 50,550 people (26,620 men and 23,930 women) will die of pancreatic cancer .
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2565&type=smp
The pancreatic cancer drugs market covered in this report is segmented –
1) By Type: Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs
2) By Drug Combination: Single, Double, Triplet, Quadruplet
3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users
The concept of combination therapy over monotherapy is one of the latest ongoing trends in the pancreatic cancer drugs market. Major players in the market understand that the combination of two or more drugs is a suitable way to increase the efficacy of the drugs and thus increase the rate of survival of patients being diagnosed with pancreatic cancer. Some of the companies investing in the combination therapy are Rafael Pharmaceuticals announced the initiation of the Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (delimitate) in combination with Modified FOLFIRINOX as first-line treatment for patients with Metastatic Pancreatic Cancer and Apexigen, Inc., a clinical-stage biopharmaceutical company, announced the presentation of new clinical data on APX005M in combination therapy in patients with metastatic pancreatic cancer.
The pancreatic cancer drugs market report table of contents includes:
1. Executive Summary
2.Pancreatic Cancer Drugs Market Characteristics
3.Pancreatic Cancer Drugs Market Trends And Strategies
4.Pancreatic Cancer Drugs Market analysis
5. Pancreatic Cancer Drugs Market Size And Growth
6. Pancreatic Cancer Drugs Segmentation
7.Pancreatic Cancer Drugs Regional And Country Analysis
.
.
.
27.Pancreatic Cancer Drugs Competitive Landscape And Company Profiles
28.Pancreatic Cancer Drugs Key Mergers And Acquisitions
29. Pancreatic Cancer Drugs Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Bristol-Myers Squibb Company
- Pfizer Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche AG
- Novartis AG
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
